Target intelligence / Profile preview

Alpha-1,2-mannosyltransferase ALG9 (ALG9)

Target
ALG9
Molecular classification
Enzyme, Glycosyltransferase, Alpha-1,2-mannosyltransferase
01

Overview

Alpha-1,2-mannosyltransferase ALG9 (ALG9) is an endoplasmic reticulum membrane enzyme critical for N-linked glycosylation of proteins. It catalyzes the addition of mannose residues to lipid-linked oligosaccharides, which are precursors necessary for proper protein folding and cellular quality control. Mutations in ALG9 cause congenital disorders of glycosylation type IL (CDG-IL), associated with multi-organ dysfunction, and have recently been linked to polycystic kidney and liver diseases. The enzyme’s activity is fundamental for glycoprotein biosynthesis, and its absence or dysfunction leads to defective N-glycosylation, accumulated misfolded proteins, and pathological organ morphology. ALG9 is essential and currently no therapeutics target its function directly, though genetic diagnosis informs patient care in relevant syndromes.

Other names
Asparagine-linked glycosylation protein 9 homologDisrupted in bipolar disorder protein 1DIBD1Dol-P-Man:Man(6)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferaseDol-P-Man:Man(8)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferaseLoss of heterozygosity, 11, chromosomal region 1 gene J productGillessen-Kaesbach-Nishimura syndrome geneCDG1LLOH11CR1JGIKANISEC 2.4.1.259EC 2.4.1.261
02

Biological functions

Protein N-glycosylation: catalyzes the transfer of mannose residues during the biosynthesis of lipid-linked oligosaccharides in the endoplasmic reticulum, affecting glycoprotein folding and quality controlOligosaccharide assembly
03

Disease associations

Congenital disorder of glycosylation type IL (ALG9-CDG)Gillessen-Kaesbach-Nishimura syndromeAutosomal dominant polycystic kidney disease (ADPKD) and polycystic liver disease (ADPLD)
04

Safety considerations

Essential for protein glycosylation—complete loss is typically lethal; partial deficiency causes severe multisystem diseaseComplex phenotype with multi-organ involvement in congenital disorders—including cardiac, hepatic, renal, and neurologic symptoms
05

Biomarkers

Hypoglycosylation of serum and tissue proteins (notable for diagnosis of congenital disorders of glycosylation)Genotyping of ALG9 for pathogenic variants (diagnostic tool for CDG-IL, ADPLD, and ADPKD)

Beyond the preview

Go deeper on Alpha-1,2-mannosyltransferase ALG9 (ALG9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-1,2-mannosyltransferase ALG9 (ALG9).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call